Total population (n=5340) | Fenofibrate (n=2673) | Placebo (n=2667) | ||||
---|---|---|---|---|---|---|
HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | |
Maximum LDL_C | ||||||
+1 SD (30 mg/dL) | ||||||
Primary outcome | 1.10 (1.01-1.20) | 0.04 | 1.15 (1.01-1.31) | 0.03 | 1.15 (1.01-1.31) | 0.03 |
All-cause deaths | 1.12 (1.01-1.23) | 0.04 | 1.16 (0.99-1.34) | 0.06 | 1.08 (0.94-1.24) | 0.30 |
Cardiovascular deaths | 1.15 (0.99-1.33) | 0.054 | 1.26 (1.02-1.56) | 0.03 | 1.05 (0.87-1.28) | 0.60 |
≥70 vs. <70 mg/dL | ||||||
Primary outcome | 0.85 (0.48-1.52) | 0.59 | 0.75 (0.33-1.69) | 0.49 | 0.98 (0.43-2.20) | 0.95 |
All-cause deaths | 0.61 (0.34-1.12) | 0.11 | 0.50 (0.21-1.24) | 0.13 | 0.70 (0.31-1.61) | 0.40 |
Cardiovascular deaths | 0.48 (0.23-1.03) | 0.06 | 0.62 (0.15-2.56) | 0.51 | 0.43 (0.17-1.07) | 0.07 |
Minimum LDL_C | ||||||
+1 SD (18 mg/dL) | ||||||
Primary outcome | 1.54 (1.41-1.67) | <0.0001 | 1.48 (1.31-1.68) | <0.0001 | 1.60 (1.42-1.80) | <0.0001 |
All-cause deaths | 1.41 (1.28-1.56) | <0.0001 | 1.31 (1.13-1.53) | 0.0005 | 1.50 (1.31-1.70) | <0.0001 |
Cardiovascular deaths | 1.54 (1.34-1.77) | <0.0001 | 1.43 (1.15-1.78) | 0.001 | 1.63 (1.36-1.96) | <0.0001 |
≥70 vs. <70 mg/dL | ||||||
Primary outcome | 2.11 (1.77-2.52) | <0.0001 | 1.95 (1.51-2.52) | <0.0001 | 2.30 (1.79-2.94) | <0.0001 |
All-cause deaths | 1.60 (1.31-1.97) | <0.0001 | 1.48 (1.10-1.99) | 0.01 | 1.73 (1.30-2.28) | 0.0001 |
Cardiovascular deaths | 2.03 (1.52-2.70) | <0.0001 | 1.70 (1.11-2.60) | 0.02 | 2.39 (1.61-3.53) | <0.0001 |